We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Perjeta First to Gain Accelerated Approval via New FDA Pathway
Perjeta First to Gain Accelerated Approval via New FDA Pathway
October 4, 2013
Genentech’s Perjeta Sept. 30 became the first drug to win approval under the FDA’s new accelerated approval pathway carved out for early-stage breast cancer before surgery.